01—Abstract
Summary
Summary of the 10-Q filed September 7, 2016. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported solid performance for the nine months ended July 31, 2016, with total net revenue increasing by 3% to $3,091 milliona compared to the prior year.
This growth was driven by strong performance in the Diagnostics and Genomics segment (+7%) and Agilent CrossLab (+6%), while the Life Sciences and Applied Markets segment remained flat. Net income from continuing operations rose to $336 millionb from $298 million in the same period last year. The company also generated significant cash flow from operations ($559 million), underscoring its financial health.
Agilent continued its commitment to shareholder returns through dividends and share repurchases, with $112 millionc in dividends paid and $290 million in shares repurchased during the nine-month period. Recent acquisitions, including Seahorse Bioscience and iLab Solutions, are expected to contribute to future growth. Financially, Agilent maintained a strong balance sheet with $2,199 million in cash and cash equivalents as of July 31, 2016.
The company also made progress on operational efficiencies and strategic initiatives, including a focus on improving operating margins. While facing some currency headwinds, Agilent demonstrated resilience and strategic execution, positioning itself for continued growth in its key markets.
02—Key points
Key Highlights
- Total net revenue increased by 3% to $3,091 million for the nine months ended July 31, 2016.
- Net income from continuing operations increased to $336 million for the nine months ended July 31, 2016, up from $298 million in the prior year.
- Strong revenue growth was observed in the Diagnostics and Genomics segment (+7%) and Agilent CrossLab segment (+6%).
- Operating cash flow remained robust at $559 million for the nine months ended July 31, 2016.
- Agilent returned value to shareholders through $112 million in dividends and $290 million in share repurchases during the nine months ended July 31, 2016.
- The company completed the acquisition of Seahorse Bioscience in November 2015 and iLab Solutions in August 2016, integrating them to drive future growth.
- Cash and cash equivalents stood strong at $2,199 million as of July 31, 2016, indicating solid liquidity.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2016, Agilent Technologies, Inc. kept $0.12.
- Revenue$1.04B100.0%
- Cost of revenue−$502.0M48.1%
- Gross profit$542.0M51.9%
- Operating costs−$396.0M37.9%
- Operating income$146.0M14.0%
- Interest, other & tax−$22.0M2.1%
- Net income$124.0M11.9%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2016filed September 7, 2016Financial Statements
Q3 FY2016 against Q3 FY2015
| Line item | Q3 FY2016Q3 FY2015 | Change |
|---|---|---|
| Revenue | $1.04B$1.01B | +3.0% |
| Cost of Revenue | $502.00M$501.00M | +0.2% |
| Gross Profit | $542.00M$513.00M | +5.7% |
| R&D Expenses | $86.00M$79.00M | +8.9% |
| SG&A Expenses | $310.00M$290.00M | +6.9% |
| Operating Expenses | $898.00M$870.00M | +3.2% |
| Operating Income | $146.00M$144.00M | +1.4% |
| Interest Expense | $17.00M$17.00M | 0.0% |
| Net Income | $124.00M$111.00M | +11.7% |
| EPS (Basic) | $0.38$0.33 | +15.2% |
| EPS (Diluted) | $0.38$0.33 | +15.2% |
| Shares Outstanding (Basic) | 325.00M332.00M | −2.1% |
| Shares Outstanding (Diluted) | 328.00M334.00M | −1.8% |
05—Questions
Frequently Asked Questions
What is Agilent's overall revenue performance for the period?
For the nine months ended July 31, 2016, Agilent Technologies reported a 3% increase in total net revenue to $3,091 million, compared to $3,003 million in the same period last year. This growth was primarily driven by the Diagnostics and Genomics segment and Agilent CrossLab segment.
How did Agilent's profitability change during this period?
Net income from continuing operations increased to $336 million for the nine months ended July 31, 2016, up from $298 million in the prior year. This improvement reflects better operational performance and revenue growth across key segments.
What is Agilent's cash flow situation?
Agilent demonstrated strong operating cash flow, generating $559 million for the nine months ended July 31, 2016. The company maintained a healthy liquidity position with $2,199 million in cash and cash equivalents as of July 31, 2016.
How is Agilent returning value to its shareholders?
Agilent continues to prioritize shareholder returns through dividends and share repurchases. During the nine months ended July 31, 2016, the company paid $112 million in dividends and repurchased approximately $290 million of its common stock. Agilent has an ongoing share repurchase program with $850 million remaining authorization as of July 31, 2016.
06—Continue